Schering Corporation

Dendreon Corporation

Other

Corvas International, Inc.

Scott Jeffrey Kemp

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

F George Njoroge

Anil K Saksena

Frank W Bennett

Stephane L Bogen

Ashok Arasappan

Raymond G Lovey

Yi-Tsung Liu

Odile Esther Levy

Patrick A Pinto

Russell E Pike

Marguerita S Lim-Wilby

Haiyan Wang

Edwin Jao

Tejal Parekh

Zhaoning Zhu

Kevin X Chen

Tin-Yau Chan

Bama Santhanam

Susan Y Tamura

Srikanth Venkatraman

Henry A Vaccaro

Yuhua Huang

Jinping L McCormick

Wanli Wu

Jinping L Mc Cormick

Siska Hendrata

Joseph Edward Semple

Jesse K Wong

Terence Kevin Brunck

Latha G Nair

Henry M Vaccaro

John Eugene Reiner

Mallareddy Komandla

Daniel Vanna Siev

Srinkanth Venkatraman

Viyyoor M Girijavallabhn

Marguerita Lim-Wilby

Edwin E Jao

Tejal N Parekh

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

Non-convalent thrombin inhibitors

Growing community of inventors

San Diego, CA, United States of America

Scott Jeffrey Kemp